Early phase clinical trials: communicating the uncertainties of 'magnitude of benefit' and 'likelihood of benefit'
- PMID: 19029213
- PMCID: PMC3110657
- DOI: 10.1177/1740774508098681
Early phase clinical trials: communicating the uncertainties of 'magnitude of benefit' and 'likelihood of benefit'
Comment on
-
Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?Clin Trials. 2008;5(6):617-23. doi: 10.1177/1740774508097576. Clin Trials. 2008. PMID: 19029210
References
-
- Siminoff LA, Fetting JH. Effects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast cancer decisions. Med Decis Making. 1989;9:262–71. - PubMed
-
- Featherstone K, Donovan JL. “Why don’t they just tell me straight, why allocate it?” The struggle to make sense of participating in a randomised controlled trial. Soc Sci Med. 2002;55:709–19. - PubMed
-
- Flory J, Emanuel E. Interventions to improve research participants’ understanding in informed consent for research. JAMA. 2004;292(13):1593–601. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
